secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kalaris Therapeutics, Inc. (KLRS)
CIK:        0001754068
Form:       8-K
Filed at:   2026-06-04T20:06:56+00:00
Accession:  0001193125-26-257388
Event type: other_material
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Kalaris Therapeutics holds 2026 annual meeting; all proposals pass
------------------------------------------------------------------

- Elected Napoleone Ferrara, David Hallal, Leone Patterson as Class III directors (three-year terms).
- Advisory vote on executive compensation approved: 15.85M for, 0.50M against.
- Shareholders recommended say-on-pay every year; board adopts annual frequency.
- Ratified Deloitte & Touche as auditor for FY 2026: 19.77M for, 1.58K against.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/0001193125-26-257388-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1754068/000119312526257388/d85626d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-257388

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer